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Abstract
The formation of a colored charge-transfer (CT) complex between atorvastatin calcium (ATR-Ca) as a n-electron donor
and 2, 3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) as a π-electron acceptor was investigated, for the first time. The
spectral characteristics of the CT complex have been described, and the reaction mechanism has been proved by
computational molecular modeling. The reaction was employed in the development of a novel microwell-based
spectrophotometric assay for determination of ATR-Ca in its pharmaceutical formulations. The proposed assay was
carried out in 96-microwell plates. The absorbance of the colored-CT complex was measured at 460 nm by microwell-
plate absorbance reader. The optimum conditions of the reaction and the analytical procedures of the assay were
established. Under the optimum conditions, linear relationship with good correlation coefficient (0.9995) was found
between the absorbance and the concentration of ATR-Ca in the range of 10-150 μg/well. The limits of detection and
quantitation were 5.3 and 15.8 μg/well, respectively. No interference was observed from the additives that are present
in the pharmaceutical formulation or from the drugs that are co-formulated with ATR-Ca in its combined formulations.
The assay was successfully applied to the analysis of ATR-Ca in its pharmaceutical dosage forms with good accuracy
and precision. The assay described herein has great practical value in the routine analysis of ATR-Ca in quality control
laboratories, as it has high throughput property, consumes minimum volume of organic solvent thus it offers the
reduction in the exposures of the analysts to the toxic effects of organic solvents, and reduction in the analysis cost by
50-fold. Although the proposed assay was validated for ATR-Ca, however, the same methodology could be used for any
electron-donating analyte for which a CT reaction can be performed.
Background
Atorvastatin calcium (ATR-Ca); [(R-(R*, R*)]-2-(4-fluoro-
phenyl)-b, δ, dihydroxy-5-(1-methylethyl)-3-phenyl-4-
[(phenyl-amino)-carbonyl]-1H-pyrrole-1-heptanoic acid
calcium salt (Figure 1), is a second generation synthetic 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase inhibitor [1]. It exerts its action by specifically
inhibiting the HMG-CoA reductase, the enzyme that cata-
lyzes the conversion of HMG-CoA to mevolanate, which
is the early rate-limiting step in the biosynthesis of choles-
terol in the body. Inhibition of the enzyme decreases de
novo cholesterol synthesis, increasing expression of low-
density lipoprotein receptors (LDL receptors) on hepato-
cytes. This increases the uptake of LDL by the hepatocytes,
decreasing the amount of LDL-cholesterol in the blood.
ATR-Ca also reduces blood levels of triglycerides and
slightly increases levels of HDL-cholesterol. ATR-Ca is the
most efficient and frequently prescribed drug for the treat-
ment of hypercholesterolaemia [2].
Atorvastatin calcium is official in USP 34 [3] and it is
analyzed in its bulk by HPLC, however the USP does not
describe an assay method for ATR-Ca in its dosage forms.
This beside the therapeutic importance of ATR-Ca was
behind the growing interest in the development of analyti-
cal methods for its determination in its pharmaceutical
formulations. In general, spectrophotometry is the most
widely used technique in pharmaceutical analysis because
of its inherent simplicity and wide availability in most
quality control laboratories [4-9]. However, the spectro-
photometric methods that have been reported for determi-
nation of ATR-Ca in its pharmaceutical formulations
[10-16] suffer from major drawbacks. These drawbacks
* Correspondence: idarwish@ksu.edu.sa
1Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud
University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
Full list of author information is available at the end of the article
Wani et al. Chemistry Central Journal 2011, 5:57
http://journal.chemistrycentral.com/content/5/1/57
© 2010 Wani et alinclude decreased selectivity due to measuring the native
light absorption of ATR-Ca in the blue-shifted ultraviolet
region, which might be subjected to interferences [12],
employment of multiple-steps of non-selective oxidation
reactions [13-15], and tedious liquid-liquid extraction pro-
cedures using large volumes of organic solvents in the
methods based on formation of ion-pair associates [16].
Therefore, the development of a new alternative spectro-
photometric method for determination of ATR-Ca in its
pharmaceutical formulations is very essential.
The molecular interactions between the electron-donat-
ing pharmaceutical compounds and electron-accepting
reagents are generally associated with the formation of
intensely colored CT complexes, which usually absorb
radiations in the visible region. The rapid formation of
these complexes leads to their widespread utility in the
development of visible spectrophotometric methods for
analysis of many pharmaceutical compounds [17-23]. Lit-
erature survey revealed that the CT reaction of ATR-Ca
has not been investigated yet. As well, in a previous study,
Darwish IA [21] demonstrated that the alkali salts of car-
boxylic pharmaceutical compounds have excellent elec-
tron-donating ability, thus it is anticipated that ATR-Ca
(the active ingredient of its dosage forms) will exhibit elec-
tron-donating capabilities. These facts promoted our inter-
est in employment of the CT-reaction as a basis for the
development of a new spectrophotometric method for
determination of ATR-Ca. However, all the conventional
CT-based spectrophotometric methods that have been
reported so far are not automated and consequently their
N
OH
F
O
OH
F
Ezetimibe 
O
Cl O
O
O
Fenofibrate 
Amlodipine besylate  
Cl
H
N
O
O
O
NH2
O
O S
OH
O O
O
O OH
O
Aspirin 
Atorvastatin calcium (ATR-Ca) 
N
F
NH
O
O
O OH OH
ņ    
    ½Ca
2+ 
Figure 1 The chemical structure of atorvastatin calcium (ATR-Ca) and the co-formulated drugs.
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Page 2 of 8throughput is low, thus their applications in pharmaceuti-
cal quality control laboratories are limited. Moreover,
these methods suffer from the consumption of large
volumes of organic solvents, which leads to high analysis
cost, and more importantly, the incidence of exposure of
t h ea n a l y s t st ot h et o x i ce f f ects of the organic solvents
[24-28].
For these reasons, the present research proposal is
devoted to investigate the CT reaction of ATR-Ca, and
its employment in the development of novel non-con-
ventional spectrophotometric assay with high analysis
throughput and can reduce the consumption of organic
solvents in the determination of ATR-Ca in its pharma-
ceutical formulations.
Experimental
Apparatus
Microwell-plate absorbance reader (ELx 808, Bio-Tek
Instruments Inc. Winooski, USA) was used for all the
measurements in 96-microwell plates. UV-1601 PC (Shi-
madzu, Kyoto, Japan) ultraviolet-visible spectrophotometer
with matched 1 cm quartz cells was used for recording the
absorption spectra. 96-Microwell plates were a product of
Corning/Costar Inc. (Cambridge, USA). Finnpipette adjus-
table 8-channel-pipette was obtained from Sigma Chemi-
cal Co. (St. Louis, MO, USA).
Chemicals and dosage forms
ATR-Ca and amlodipine besylate were obtained from Pfi-
zer Inc. (New York, USA). Ezetimibe was obtained from
AK Scientific Inc. (California, USA). Fenofibrate, and
aspirin were obtained from Sigma Chemical Co. (St. Louis,
USA). DDQ (Merck, Germany) was 0.1% (w/v) in metha-
nol and it was prepared fresh daily. Lipitor tablets (Parke
Davis, Germany) and Lipicure-10 tablets (INTAS Pharma-
ceuticals, India) labeled to contain 10 mg ATR-Ca were
obtained from the local market.
Preparation of atorvastatin from ATR-Ca
An accurately weighed amount (25 mg) of ATR-Ca was
dissolved in 10 ml water in a test tube. The solution was
transferred into a 100-ml separating funnel, then rendered
acidic with 10% HCl. The liberated atorvastatin (acid
form) was extracted by chloroform. The chloroformic
solution was evaporated under nitrogen, and the obtained
residue was reconstituted in methanol. The methanolic
solution was tested for its ability to exhibit CT reaction.
Preparation of standard and tablet solutions
Preparation of stock standard solutions
Into a 5-ml calibrated flask, 10 mg of ATR-Ca was accu-
rately weighed, dissolved in 2 ml methanol, and completed
to volume with the same solvent. This stock solution was
diluted with methanol to obtain the suitable concentra-
tions that lie in the linear range of the assay.
Preparation of tablet sample solutions
Twenty tablets were weighed and finely powdered. A
quantity of the powder equivalent to 20 mg of ATR-Ca
was transferred into a 10-ml calibrated flask, dissolved in
4 ml methanol, swirled and sonicated for 5 min, com-
pleted to volume with the methanol, shaken well for
15 min, and filtered. The first portion of the filtrate was
rejected, and a measured volume of the filtrate was diluted
quantitatively with methanol to yield the suitable concen-
trations that lie in the linear range of the assay.
General analytical procedure
Accurately measured aliquots (100 μl) of the standard or
sample solution containing varying amounts of ATR-Ca
(10-150 μg) were transferred into wells of 96-microwell
assay plates. One hundred microliters of DDQ solution
(0.1%, w/v) was added, and the reaction was allowed to
proceed at room temperature (25 ± 1°C) for 5 min. The
absorbances of the resulting solutions were measured at
460 nm by the microwell-plate reader. Blank wells were
treated similarly except 100 μl of methanol was used
instead of sample, and the absorbances of the blank wells
were subtracted from those of the other wells.
Determination of molar ratio
The Job’sm e t h o do fc o n t i n u o u sv a r i a t i o n[ 2 9 ]w a s
employed. Master equimolar solutions (2 × 10
-3 M) of
each of ATR-Ca and DDQ were prepared. Series of 200 μl
portions of the master solutions of ATR-Ca with DDQ
were made up comprising different complementary ratios
(0:10, 1:9, ........., 9:1, 10:0, inclusive) in each well of the
96-microwell assay plate. The reaction was allowed to pro-
ceed at room temperature (25 ± 1°C) for 5 min. The
absorbances of the developed colors were measured at
460 nm by the microwell-plate reader against blank wells
treated similarly except methanol was used instead of
ATR-Ca sample. The measured absorbances were plotted
as a function of ATR-Ca mole fraction. The generated
plot was used for determination the molar ration of ATR-
Ca:DDQ.
Molecular modeling for the CT complex of ATR-Ca with
DDQ
The molecular modeling for the CT complex was per-
formed by using CS Chem3D Ultra, version 9 (Cambridge
Soft Corporation, Cambridge, MA, USA) implemented
with molecular orbital computations software (MOPAC),
and molecular dynamics computations software (MM2).
Results and Discussion
Design of the proposed assay and strategy for its
development
The proposed assay was designed to employ 96-micro-
well assay plate as the CT reaction was carried out in
microwells of the assay plate (200-μl reaction volume)
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volume). The solutions were dispensed by 8-channel pip-
ette, and the absorbances of the colored CT complex
were measured by microwell-plate absorbance reader
instead of the conventional spectrophotometer.
In the present study, ATR-Ca was selected based on
its therapeutic importance, clinical success, and the
expected electron-donating ability. This selection was
supported by a previous study made by Darwish IA [21],
which demonstrated the excellent electron-donating
property of alkali salts of carboxylic acid pharmaceutical
compounds. Previous studies involving CT reactions
with polyhalo-/polycyanoquinone electron n-acceptors
revealed that DDQ is one of the most efficient reagents
in terms of its reactivity [21,30]. Furthermore, its CT
reaction with electron-donating analytes is instantaneous
[21,22]. For these reasons, DDQ was used as electron
acceptor in the development of the proposed assay. The
96-microwell design of the proposed assay was based on
the previous success of Darwish et al [31] in the utility
of this design for determination of some other
pharmaceuticals.
Reaction and spectral characteristics
The interaction of ATR-Ca with DDQ was allowed to
proceed at room temperature, and the absorption spec-
trum of the produced chromogen was recorded. ATR-
Ca gave red colored chromogen showing absorption
maximum at 460 nm (Figure 2). This band was attribu-
ted to the formation of the radical anion DDQ
- [32],
which was probably formed by the dissociation of an
original donor-acceptor (D-A) complex:
D+A (D-A )
complex
polar
solvent
 D .+ +A.-
radical ions
Further support of this assignment was provided by
the absorption maxima with those of DDQ radical anion
produced by the iodide reduction assay [32]. The disso-
ciation of the (D-A) complex was promoted by the high
ionizing power of the polar solvent and the resulting
peaks in the absorption spectra of drug-acceptor reac-
tion mixtures were similar to the maxima of the radical
anions of the acceptors obtained by the iodide reduction
assay [32].
Optimization of experimental conditions
The optimization of experimental conditions affecting
the reaction in the 96-well format was investigated by
altering each reaction variable in a turn while keeping
the others constant. In all cases, measurements were
carried out at 460 nm, as this maximum gave the high-
est absorptivities and ultimately the highest analytical
sensitivities. The results of variations in the DDQ con-
centrations indicated that 100 μlo f0 . 1 %( w / v )w a st h e
optimum DDQ concentration, as this concentration
gave the highest absorbances. Previous studies [33]
demonstrated that the interaction of electron-donors
with DDQ in polar solvents (e.g. methanol and acetoni-
trile) produces CT complexes with molar absorptivity
values higher than those produced in non-polar solvents
(e.g. chloroform). Different polar solvents were tested as
reaction solvent; these solvents were methanol, ethanol,
1-propanol, 1-butanol, and acetonitrile. The obtained
Figure 2 Absorption spectrum of (1) ATR-Ca (125 μg/ml) and (2) reaction product of ATR-Ca (125 μg/ml) with DDQ (0.1%, w/v).
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respectively. These values indicated that methanol
offered the highest sensitivity, therefore it was selected
for the subsequent experiments. As well, these solvents
has no any harmful effect on the transparency of the
microwells. The optimum reaction time was determined
by monitoring the color development in the microwells
at room temperature (25 ± 1°C). Complete color devel-
opment was attained instantaneously, however for
higher precision readings, the reaction was allowed to
proceed for 5 min. The developed color remained stable
at room temperature for at least a further 30 min.
Molar ratio of the reaction, molecular modeling, and
proposing the site of interaction
Job’s method of continuous variation was used for deter-
mining the molar ratio of ATR-Ca to DDQ. The obtained
Job’sp l o tw a sg i v e ni nF i g u r e3 ,f r o mw h i c hi tw a sc o n -
cluded that the ATR-Ca:DDQ ratio is 1:2. This indicated
that two moles of DDQ interacted with one mole of ATR-
Ca. Considering the divalent calcium ion, the reaction was
postulated to proceed as 1:1 ratio for DDQ with atorvasta-
tin anion via only one site of interaction in spite of the
presence of more than one possible electron-donating
sites; OH of the side chain and the nitrogen atom of pyrole
ring. The site of interaction was preliminarily postulated to
be the anionic carboxylate moiety of ATR-Ca. To prove
this suggestion, the CT reaction was carried out using the
parent atorvastatin acid. It was found that atorvastatin did
not exhibit CT reaction indicating that the anionic carbox-
y l a t em o i e t yo fA T R - C aw a st h es i t eo fC Ti n t e r a c t i o n
with DDQ. For further support of this assumption, model-
ing for the CT complex was performed. Atorvastatin
anion and DDQ were energy-minimized alone and both
together. It was found that the highest electron densities
in the atorvastatin molecule are located on the two oxygen
atoms of the carboxylate anion followed by the two
alcoholic oxygen atoms of the side chain. The total
charges on each of the two oxygen atoms of the carboxy-
late anion were found to be -0.6234 and -0.5975. There-
fore, it is expected that the carboxylate anion moiety of
ATR-Ca will move toward DDQ to form the CT complex
(Figure 4). These facts, taking the molar ratio in account,
confirmed that only the carboxylate oxygens are involved
in the complex formation, and the reaction proceeded as
described in Figure 5. The nitrogen atom of the pyrole
ring and OHs of the side chain did not contribute in the
CT reaction based on the fact that certain electron density
was required for achievement of a successful electron
transfer [34].
Validation of the proposed assay
Linearity and sensitivity
Under the above mentioned optimum reaction conditions,
the calibration curve for the analysis of ATR-Ca by the
proposed assay was constructed by plotting the absor-
bances as a function of the corresponding concentrations.
The regression equation for the results was derived using
the least-squares method. Beer’s law plot (n = 5) was linear
with very small intercept (0.0045) and good correlation
coefficient (0.9995) in the concentration range of 10 - 150
μg/well (100 μl). The limits of detection (LOD) and quan-
titation (LOQ) were determined [35] using the formula:
LOD or LOQ = SDa/b, where  = 3 for LOD and 10 for
LOQ, SDa is the standard deviation of the intercept, and b
is the slope. The LOD and LOQ values were 5.3 and
15.8 μg/well (100 μl), respectively. The quantitative para-
meters of the proposed assay are given in Table 1.
Accuracy and precision
Accuracy of the proposed assay was assessed by analytical
recovery studies. Recovery was determined by the stan-
dard addition method. Known amounts of ATR-Ca were
added to pre-determined drug-containing pharmaceutical
formulation, and then determined by the proposed assay.
The mean analytical recovery was calculated and found
to be 97.03-99.91 ± 0.33-3.49% indicating the accuracy of
the proposed assay.
The precisions of the proposed assay were determined
on samples of drug solutions at three concentration levels
for each drug (Table 2) by analyzing 5 replicates of each
sample as a batch in a single assay run. The relative stan-
dard deviations (RSD) did not exceed 1.48% (Table 2)
proving the high precision of the assay for the routine
application in quality control laboratories. This high level
of precision was attributed to the accuracy of the
volumes that have been concomitantly dispensed in the
microwells by multi-channel pipettes, and completeness
of the reaction the small volume (200 μl).
Selectivity
The proposed assay has the advantages that the measure-
ments are performed in the visible region, away from the
Figure 3 Job’s plot for CT reaction of ATR-Ca with DDQ.
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extracted from dosage forms that contain ATR-Ca. The
interference from the congenital drugs that is co-formu-
lated with ATR-Ca in some of its dosage forms was stu-
died. These drugs were aspirin [36], fenofibrate [37],
ezetimibe [38] and amlodipine besylate [39,40]; the che-
mical structures of these drugs are given in Figure 5.
Potential interferences of these drugs were studied in a
ratio which is normally present in their combined dosage
forms. No interferences from these drugs were found
with ATR-Ca in the proposed assay. Although, amlodi-
pine has basic character, however it is co-formulated
with ATR-Ca as besylate salt that did not show any abil-
ity for CT reaction with DDQ under the proposed assay
Atorvastain anion CT complex of atorvastatin 
anion with DDQ  
Figure 4 Energy-minimized atorvastatin anion and its CT complex with DDQ.
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Figure 5 Mechanism of CT reaction of ATR-Ca with DDQ.
Table 1 Quantitative parameters for the analysis of ATR-
Ca by the proposed assay
Parameter Value
Range (μg/well)
a 10-150
Intercept 0.0045
Slope 0.0066
Correlation coefficient 0.9995
Molar absorptivity (L/mol/cm) 675
LOD (μg/well)
a 5.3
LOQ (μg/well)
a 15.8
a Each well contained 100 μl of ATR-Ca sample.
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the excipients with the proposed assay as indicated from
the obtained good recovery (mentioned above). The
absence of interference from the excipients, even though
they contain basic component(s) was attributed to the
extraction of the ATR-Ca tablets prior to the analysis
with methanol in which the excipients do not dissolve.
Application of the proposed assay in the analysis of
pharmaceutical formulations
The commercially available pharmaceutical formulations of
ATR-Ca were subjected to the analysis by the proposed
and reported methods [15] and the obtained results were
then statistically compared with each other. The mean per-
centage recoveries, relative to the labeled amounts,
obtained by the proposed assay were 97.24 ± 1.50 and
99.82 ± 1.05% for lipitor and lipicure-10 tablets, respec-
tively (Table 3). In the t- and F-tests, no significant differ-
ences were found between the calculated and theoretical
values of both the proposed and the reported assays at 95%
confidence level. This indicated similar accuracy and preci-
sion in the analysis by the proposed and reported methods.
Conclusions
The present study described the development and vali-
dation of a novel microwell-based spectrophotometric
assay for the determination of ATR-Ca based on its CT
reaction with DDQ reagent. In this assay, the CT reac-
tion was carried out in 96-microwell plates (200-μl reac-
tion volume) instead of the conventional volumetric
flasks (10,000-μl volume). The absorbances were mea-
sured by microwell-plate reader instead of the conven-
tional spectrophotometer. The assay described herein
offered the following advantages:
- Reduction in the consumption of organic solvents in
the CT-based spectrophotometric analysis, accordingly
reduction in the exposures of the analysts to the toxic
effects of organic solvents.
- Reduction in the analysis cost by 50-folds which can
be reflected on the price for the finished dosage forms,
thus it can reduce the expenses for the medications.
- Providing a high throughput analytical methodology
that can facilitate the processing of large number of
samples in a relatively short time. This property was
attributed to the use of multi-channel pipettes for effi-
cient dispensing of the solutions, carrying out the analy-
tical reaction in 96-well plates (as reaction vessels), and
measuring the color signals in the 96 wells at ~ 30 sec-
onds by the plate reader.
- The advantages of the proposed assay and in addi-
tion to automation could be reached by application of
Flow Injection Analysis.
- Although the proposed assay was developed and
validated for ATR-Ca, however, it is also anticipated
that the same methodology could be used for essentially
any analyte that can exhibit CT reaction.
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